When does Lundbeck’s “Lundbeck LOE” related to Vyepti (eptinezumab) expire?
Lundbeck’s “LOE” (loss of exclusivity) date for Vyepti depends on the specific country and the exact exclusivity mechanism being referred to (for example, primary patent expiry versus other forms of exclusivity). The information provided here does not include Lundbeck’s LOE date or any country-specific exclusivity details for Vyepti, so the exact expiry date can’t be confirmed from the available material.
Is the LOE date the same as patent expiry for Vyepti?
LOE and patent expiry can differ. In many markets, exclusivity can end later or earlier than the first patent’s expiration depending on what protections are in force (multiple patents, secondary patents, and regulatory exclusivity). To determine whether LOE aligns with the patent expiry, you’d need the specific LOE and patent numbers (and the jurisdiction).
Which country matters for the Vyepti exclusivity/expiry timeline?
Exclusivity timelines vary by jurisdiction (e.g., the US vs. EU can have different rules and durations). Without the target market (US, EU, UK, etc.) and the specific LOE reference, there is no single definitive “Lundbeck LOE for Vyepti” date.
Where can I verify Lundbeck’s exact Vyepti LOE date?
To get the precise LOE expiry, you typically verify the claim in sources that list:
1) the product (Vyepti) and active ingredient (eptinezumab),
2) the jurisdiction,
3) the specific Lundbeck protection record being summarized as “LOE,” and
4) the stated end date.
If you share the country (and, if possible, the document or slide where you saw “Lundbeck LOE vyepti”), I can help interpret what protection type it refers to and how it maps to patent expiry for that market.
Sources
No sources were provided in the prompt, so no citations are included.